BHIVA 14 th Annual Conference April 2008 Belfast

BHIVA 14 th Annual Conference April 2008, Belfast Waterfront Hall

BHIVA 14 th Annual Conference • • 500 delegates 200 Poster presentations 30 oral abstracts 10 Satellite symposiums 5 Plenary sessions 3 big workshops Presentation of awards for 3 best abstracts of the conference by the Mayor of Belfast.

Relevant abstracts • • Immunotherapy while delaying HAART 350 CD 4 threshold for starting therapy Protease Inhibitors monotherapy Diagnosing the undiagnosed Ageing of the PLH population HIV treatment adherence for adolescents Community HIV treatment adherence support The importance of home delivery for ARVs

Diagnosing the undiagnosed • Targeted prevention – Communities – Primary Care HIV testing • Background – CDC – routine testing of 13 -64 olds to reduce late presentations • Methods – Past diagnosed prevalence for MSM and HS MSM - 0. 25% prevalence and black women 2%

Diagnosing the undiagnosed • Conclusion – Localised approach of targeting offers HIV testing based on simple risk assessments. – It allows local patient acceptability, setting appropriateness and partner notification.

Protease Inhibitors mono-therapy The KIMODO Study • Kaletra (Lopinavir + Ritonavir) monotherapy • Kaletra + Sustiva/Neviralpine • No significant difference between the two • Benefits – Less toxicity – Better adherence – Better resistance profile

Immunotherapy while delaying HAART

350 CD 4 threshold for starting therapy

Ageing of the PLH population • • Cardiovascular disease Diabetes Dementia Physical weakness – Care for elderly – Mobility • Sensory impairment • Living will/Funeral arrangements…

New Drugs • Celsentri (Maraviroc) – CCR 5 antagonist • Isentress (Raltegravir) – Integrase inhibitor • Atripula od (Tenofovir+ Emtrica +Sustiva)